Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

This volume provides an in-depth review of the data relating to the management of renal tumors as well as an updated description regarding pathologic and molecular classification of renal tumors. The neoplasms covered include clear cell carcinomas, papillary cancers, nonepithelial tumors, and other mass lesions that resemble tumors. The management of patients with renal cancer having localized or advanced disease is discussed. Surgical approaches for primary and metastatic tumors, symptom palliation, and systemic therapy for metastatic disease including immunotherapy and targeted approaches are discussed in detail.

Distinguished physicians and researchers from prestigious Cancer Centers around the world offer their expertise in current and innovative management of cancer in the spine. These authors bring together the latest thinking from diverse fields of medicine to provide, in one volume, a guide to coordinated management of all aspects of spinal tumors covering chemo- and radiation therapy, pain management, diagnostic radiology, as well as reconstructive surgery and palliative care. Highlights include management of vertebral metastases, innovations in radiotherapy, treatment of pathological fractures, curative strategies for primary malignancies, as well as a guide to pain management and end-of-life care.

The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.

The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.

Advanced renal cell carcinoma is refractory to nearly forms of systemic therapy. For this reason the last decade has seen numerous research groups working on immunotherapeutic s trategies against it. Immunotherapy of Renal Cell Carcinoma reports the contributions of most of the world's leading re- search groups to two international conferences on the immu- nobiology of this illness. Sixteen chapters divided in expe- rimental and clinical studies provide an overview of immuno- therapy in renal cell carcinoma and a discussion of new la- boratory approaches to this topic.

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.